NewAmsterdam Pharma Unveils Promising Results from BROADWAY Trial, Highlighting Obicetrapib’s Impact on Alzheimer’s Biomarkers
Reuters
Jul 30
NewAmsterdam Pharma Unveils Promising Results from BROADWAY Trial, Highlighting Obicetrapib's Impact on Alzheimer's Biomarkers
NewAmsterdam Pharma Company NV has announced the results of the Phase 3 BROADWAY clinical trial, which were presented at the 2025 Alzheimer's Association International Conference $(AAIC)$ in Toronto. The trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo in reducing Alzheimer's disease biomarkers. The analysis revealed that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, in both the full analysis set and in ApoE4 carriers. In APOE4/E4 carriers, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo. The findings suggest that CETP inhibition could be a potential novel approach for Alzheimer's prevention. These results build on obicetrapib's existing cardiometabolic profile, which has shown reductions in LDL-C, small dense LDL particles, Lipoprotein(a), and biomarkers associated with diabetes and kidney function in previous trials. NewAmsterdam Pharma plans to discuss these findings with regulatory authorities to determine potential next steps.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9502816-en) on July 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.